Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers
- PMID: 1748138
- DOI: 10.1007/BF00315432
Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers
Abstract
Possible local and systemic adverse effects following administration of salmon (sCT) and human (hCT) calcitonin (CT) have been evaluated in a double-blind, within-subject, comparative trial in 30 young, healthy volunteers. Each subject received 0.25 and 0.5 mg hCT and 100 IU sCT s.c.. Adverse effects and hypocalcaemia were recorded 1, 3 and 6 h after each injection. Significantly fewer local adverse reactions were observed after hCT (20 or 33%) than after sCT (80%), possibly due to the different vehicles employed (mannitol solution and acetic acid). The most frequent systemic adverse effects were gastrointestinal (nausea, vomiting), which occurred in 80% after 1 h, independently of the CT--preparation used. Hypocalcaemic changes were generally small and lasted longer after sCT. It is concluded that the hCT preparations were better tolerated locally than sCT in young, healthy volunteers, and that there were no differences in the systemic side effects or hypocalcaemic activity.
Similar articles
-
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.J Bone Miner Res. 2004 Sep;19(9):1531-8. doi: 10.1359/JBMR.040715. Epub 2004 Jul 26. J Bone Miner Res. 2004. PMID: 15312255 Clinical Trial.
-
A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia.Scand J Rheumatol. 1998;27(2):112-6. doi: 10.1080/030097498440976. Scand J Rheumatol. 1998. PMID: 9572636 Clinical Trial.
-
A chimeric analog of human and salmon calcitonin eliminates antigenicity and reduces gastrointestinal disturbances.Endocrinology. 1992 Dec;131(6):2885-90. doi: 10.1210/endo.131.6.1280207. Endocrinology. 1992. PMID: 1280207
-
Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers.J Bone Miner Res. 2002 Aug;17(8):1478-85. doi: 10.1359/jbmr.2002.17.8.1478. J Bone Miner Res. 2002. PMID: 12162502 Clinical Trial.
-
Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats.J Pharm Pharmacol. 1992 Mar;44(3):216-8. doi: 10.1111/j.2042-7158.1992.tb03584.x. J Pharm Pharmacol. 1992. PMID: 1354726
Cited by
-
Structure of peptide solutions: a light scattering and numerical study.Eur Phys J E Soft Matter. 2004 Feb;13(2):153-64. doi: 10.1140/epje/e2004-00051-2. Eur Phys J E Soft Matter. 2004. PMID: 15052425
-
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.Nat Rev Endocrinol. 2025 Aug;21(8):482-494. doi: 10.1038/s41574-025-01125-9. Epub 2025 May 13. Nat Rev Endocrinol. 2025. PMID: 40360789 Review.
-
Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.Clin Rheumatol. 2006 Sep;25(5):683-6. doi: 10.1007/s10067-005-0159-0. Epub 2006 Jan 4. Clin Rheumatol. 2006. PMID: 16391891 Clinical Trial.
-
Calcitonin: A useful old friend.J Musculoskelet Neuronal Interact. 2020 Dec 1;20(4):600-609. J Musculoskelet Neuronal Interact. 2020. PMID: 33265089 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources